MBX Biosciences, Inc. (MBX)
| Market Cap | 363.58M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -55.18M |
| Shares Out | 33.42M |
| EPS (ttm) | -4.01 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 136,615 |
| Open | 11.99 |
| Previous Close | 11.83 |
| Day's Range | 10.81 - 12.31 |
| 52-Week Range | 8.63 - 27.50 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 37.25 (+242.37%) |
| Earnings Date | Feb 28, 2025 |
About MBX
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 cl... [Read more]
Analyst Forecast
According to 4 analysts, the average rating for MBX stock is "Strong Buy." The 12-month stock price forecast is $37.25, which is an increase of 242.37% from the latest price.
News
MBX Biosciences to Participate in March Investor Conferences
CARMEL, Ind., Feb. 18, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide ther...
MBX Biosciences Announces Positive Phase 1 Topline Results for MBX 1416 for the Treatment of Post-bariatric Hypoglycemia
Phase 1 results support proceeding to Phase 2 in patients with post-bariatric hypoglycemia (PBH) , which is expected to begin in 2H 2025
MBX Biosciences Announces Last Subject Last Visit in Phase 1 Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia
CARMEL, Ind., Nov. 18, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide ther...
MBX Biosciences to Participate in Upcoming November Investor Conferences
CARMEL, Ind., Oct. 28, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide ther...
MBX Biosciences Presents MBX 2109 Phase 2 Avail™ Hypoparathyroidism Trial Rationale and Design at the ASBMR 2024 Annual Meeting
CARMEL, Ind., Sept. 30, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide the...
MBX Biosciences Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
CARMEL, Ind., Sept. 16, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX) (“MBX Biosciences”), a clinical-stage biopharmaceutical company focused on the discovery and development of novel p...
U.S. IPO Weekly Recap: 3 Biotechs Lead Active September IPO Market
Six IPOs debuted this past week, including three deals of more than $100 million. Seven IPOs submitted initial filings. Outparcel REIT FrontView REIT filed to raise $100 million, and Chinese on-demand...
MBX Biosciences shares surge 44% in blockbuster Nasdaq debut
Shares of MBX Biosciences , which is developing therapies that target endocrine and metabolic disorders, including diabetes and obesity, rose nearly 44% in their Nasdaq debut on Friday, underscoring i...
MBX Biosciences raises $163.2 mln in US IPO
MBX Biosciences, which is developing peptide therapies for treating endocrine and metabolic disorders, including diabetes and obesity, said on Thursday it has raised $163.2 million in its U.S. initial...
MBX Biosciences Announces Pricing of Initial Public Offering
CARMEL, Ind., Sept. 12, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX) (“MBX Biosciences”), a clinical-stage biopharmaceutical company focused on the discovery and development of novel p...
MBX Biosciences Announces Launch of Initial Public Offering
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company focused on the...
MBX Biosciences IPO Registration Document (S-1)
MBX Biosciences has filed to go public with an IPO on the NASDAQ.